Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil TCI vs Standard Sedation for EBUS-TBNA
NCT06033729Completed
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, single-blind trial of remifentanil in lung cancer (2 arms). Primary endpoints: Patient comfort and satisfaction to the procedure, Bronchoscopist comfort and satisfaction to the procedure and 1 more. Started Sep 2021; status: completed.
02
Drugs
remifentanil
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06033729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033729.